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Abstract 
 
Diabetes mellitus is a chronic metabolic disorder which has become a major risk to the health 
of mankind, as its prevalence is increasing rapidly, globally. Currently available treatment 
options in modern medicine have several adverse effects. Thus, an accumulative need to 
develop alternative, cost effective, safe and active treatment for diabetes is necessary. 
Warburgia salutaris is a traditional medicinal plant which is used in treating numerous 
ailments. In this study, the stem bark of W. salutaris was extracted with dichloromethane from 
a compound NN-01 was isolated by means of column chromatography technique. 
Spectroscopic analysis (1H NMR, 13C NMR and MS) was used to identify NN-01 as Mukaadial 
acetate. The structure was verified by X-ray crystallography technique. Cytotoxicity and 
glucose utilisation screening assays (in vitro) were determined using L6 cells.  α- Amylase and 
α-glucosidase inhibitory activity was executed in vitro. 1,1-diphenyl-2- picrylhydrazyl was 
used to determine antioxidant activity. Antidiabetic study (in vivo) was conducted by inducing 
diabetes mellitus in male Sprague-Dawley rats with a single i.p injection of streptozotocin (60 
mg/kg). M. acetate (0.5, 1.5 and 2.5mg/kg) and crude extract (1.5mg/kg) were administered as 
treatment options, with acarbose as a positive control. Parameters such as blood glucose and 
insulin concentration, haematology, food intake, water intake, weight change and urine volume 
were determined. Harvesting of the liver, muscle, kidneys and pancreas was done at the end of 
experimental study period for further analysis. 
 
The cell viability effect of M. acetate was highest at 3µg/ml with a percentage of 98.4. M. 
acetate also significantly and dose dependently increased glucose utilisation up to 215.18% 
(12.5µg/ml). The crude extract and M. acetate dose dependently inhibited the enzymes α-
amylase and α-glucosidase. A scavenging activity against DPPH was displayed by both the 
crude extract and M. acetate in a concentration dependent manner. M. acetate and crude extract 
did not exhibit blood glucose-lowering activity against STZ, with no significant increase in 
plasma insulin concentration compared to the control. However, M. acetate and crude extract 
displayed a protective effect by stabilizing body weight of STZ-induced animals. Furthermore, 
M. acetate was capable of normalizing some haematological parameters induced by STZ.  
 
The compound M. acetate isolated from W. salutaris, revealed considerable cytotoxicity with 
a significant effect on glucose utilisation in vitro. It was further observed that the compound 
iv 
 
prevented the delivery and absorption of carbohydrates in vitro, by inhibiting the key 
carbohydrate metabolising enzymes. M. acetate also displayed a promising scavenging effect 
on free radicals in vitro. However, in vivo M. acetate exhibited no hypoglycaemic effect, 
therefore, further studies are required to confirm the promising therapeutic efficacy of M. 
acetate. 
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Chapter 1 
Introduction 
 
Diabetes is a word denoted from the Greek word siphon, as the affected individuals experience 
polyuria (pass water like a siphon) [1]. Diabetes is classified into mellitus or less often, 
insipidus [1]. However, the term is often used without qualification, designating it as diabetes 
mellitus [1]. Diabetes mellitus (DM) is a metabolic disorder characterised by chronic raised 
plasma glucose levels as a result of inadequate insulin emission, insulin action or both [2], 
affecting the body in terms of physical, psychological and social health [3]. The disorder is due 
to dysfunction of the pancreatic β-cell, whereby insulin production is impaired or lost, or a 
defective form of insulin is secreted  [4].  
 
In 1980, the World Health Organization (WHO) reported that 108 million people were 
diagnosed with diabetes and it is estimated the number has quadrupled to 422 million thus far 
[5]. It was estimated between 2000 and 2012 that DM was the eighth prevalent cause of 
mortality among diseases like Cardio Vascular Disease, Pneumonia, HIV/AIDS and Chronic 
Obstructive Pulmonary Disease [6]. WHO has projected that by 2030 diabetes will be the 7th 
main cause of mortality [5], as the number of people with diabetes is likely to double by the 
year 2030 [2]. This increasing number is due to aging, urbanization, population growth and the 
escalating prevalence of physical inactivity and obesity [7].  
 
The conventional DM treatment options use blood glucose-lowering agents, however these 
have limitations [8]. Moreover, in low socio-economic countries conventional drugs are not 
easily accessible. These restrictions have created a crucial need to find effective and affordable 
treatments for the progression of DM [9]. Hence, there has been a sudden interest in researchers 
to evaluate alternative medicine and natural therapies, particularly medicinal plants [2]. These 
plants have been used in developing countries to treat numerous diseases, including DM [10]. 
Previous studies have clinically evaluated these plants to possess significant antidiabetic 
properties [11]. Furthermore, phytochemicals accountable for these antidiabetic properties 
have been isolated over the years from plants. Thus, WHO has recommended the investigation 
on medicinal plants as antidiabetic treatment options, as they are deduced to be nontoxic, 
effective, with minimum adverse effects and affordable [3]. 
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1.1 Structure of the dissertation 
 
Chapter 1: This chapter provides the background on diabetes mellitus, outlining its 
problematic proclamation. 
 
Chapter 2: This chapter gives detailed information on diabetes mellitus: antiquity, 
classification, diagnosis, complications and the therapeutic interventions of diabetes. The 
selected plant for this study has also been discussed briefly in this chapter. 
 
Chapter 3: The chapter provides the methodologic outline of the stated study. 
 
Chapter 4: The chapter gives an overview of the findings of the present study. 
 
Chapter 5: This chapter provides the discussion of the results connecting it to literature.  
 
Chapter 6: This chapter gives a brief conclusion of the findings of the present study. 
Recommendations are also looked at in this chapter. 
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Chapter 2 
Literature Review 
 
2.1 Prevalence of Diabetes Mellitus in Africa 
 
Diabetes mellitus is a disease that has been rapidly growing. In 1985, an estimated 30 million 
people suffered from this chronic disease which increased to 230 million in 2006, accounting 
for 6% of the world population. A percentage of 80 of this number was found to be in 
developing countries [12], with 5.1% of the population in Africa diagnosed with diabetes and 
76% of the mortality rate occurring in diabetic people under the age of 60 [13].  In the next two 
decades, the number of individuals in Africa to be afflicted with diabetes is estimated to 
escalate substantially [14]. However, diabetes still remains one of the largest chronic diseases 
regardless of the alarming statistics [1].  
 
 
Figure 2.1: Prevalence of Diabetes worldwide with 5.1 % of the African continent 
diagnosed with diabetes. [15] 
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2.2 Antiquity of Diabetes Mellitus 
 
Diabetes mellitus (DM) is a disorder which was identified by ancient Egyptians, approximately 
more than 3000 years ago [16]. Araetus of Cappodocia (81-133AD) invented the word 
“Diabetes” and in 1675, Thomas Willis (Britain) added the word “Mellitus”, as he noted that 
diabetic urine had a sweet-taste as honey [17]. Mering and Minkowski (1889) discovered that 
the pancreas played a role in the pathogenesis of DM and this finding later established the basis 
of insulin isolation by Banting and Best (1921) [17]. Therefore it has been conceptualized that 
excess glucose production causes DM [2, 18].  
 
2.3 The role of Insulin in Metabolism and Diabetes Mellitus 
 
Insulin, a natural hormone produced by beta cells of the pancreatic islets of Langerhans [19], 
is a polypeptide with an amino acid sequence, comprising of A and B chains connected by 
disulphide bridges (Fig 1.2) [19]. It maintains blood glucose levels in the human body by 
accelerating the uptake of glucose via glucose transporter 4 (GLUT4), into the skeletal muscle 
fibre and adipocytes [20]. Insulin also regulates the stimulation of lipid, carbohydrate and 
protein metabolism as well as the transcription of RNA and DNA [21]. Therefore allowing the 
storage of glucose into glycogen in the liver and skeletal muscle, and deposition of triglycerides 
in the adipose tissue [20].  
 
 
 
Figure 2.2: Structure of human proinsulin. Insulin’s A (green) and B (yellow) chains 
linked by C-peptide (red) [22] 
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Insulin synthesis in the beta cells begins with translation of the insulin RNA by ribosomes 
attached to the endoplasmic reticulum (ER) forming an insulin preprohormone; preproinsulin 
[23]. This hormone is translocated into the lumen of the ER, cleaving its signal peptide in the 
ER producing proinsulin. This hormone in turn undergoes scrupulous protein folding, most of 
this is further cleaved in the Golgi apparatus and packed into secretory vesicles. The translation 
of proinsulin to insulin occurs in the secretory vesicles and released by exocytosis [24]. 
 
Beta cells of the pancreas are responsible for secreting insulin to regulate blood glucose levels. 
The increase in glucose metabolism elevates adenosine triphosphate (ATP) which affects the 
plasma membrane by inhibiting the ATP-sensitive K+ channels. The opening of Ca2+ channels 
occurs as the cell membrane depolarizes leading to Ca2+ influx. When Ca2+ and ATP levels 
rise, the plasma membrane fuses with vesicles enclosing insulin, causing insulin release from 
the cell [25]. Insulin activates translocation of glucose transporters into the adipose and muscle 
tissue cell membrane, causing glucose to be transported into the cells. To achieve this action 
insulin binds to plasma receptor proteins situated on insulin responsive tissues. The insulin 
receptor contains the binding fraction, α subunit and two β subunits (comprising tyrosine 
kinase), connected by disulphide bonds. As insulin binds to the receptor it causes 
autophosphorylation of tyrosine kinase, phosphorylating the insulin receptor substrates (IRS- 
1, 2, 3 and 4) in turn. The phosphorylated substrates bind to SH2 domains, specifically 
phosphatidylinositol-3-kinase (PI3-K). The activation of PI3-K promotes phosphatidylinositol 
3,4,5-trisphosphate (PIP3) generation. Thus, stimulating the phosphorylation of 
phosphoinositide-dependent protein kinase 1 (PDK1), activating protein kinase C (PKC) and 
protein kinase B (PKB) or AKT. The activation of AKT is essential in stimulating GLUT4 
translocation towards the plasma membrane, to facilitate the uptake of glucose into the adipose 
and muscle tissues [8, 26].  
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Figure 2.3: The activation of insulin receptors by their ligands. [8] This initiates a number 
of phosphorylation actions (i.e. phosphorylation of insulin receptor substrate). IRS proteins 
activates the P13K- pathway by activating P13K, resulting in the production of second 
messenger PIP3. This activates PDK-1, phosphorylating and activating Akt and PKCs. 
Therefore, stimulating GLUT4 translocation  towards the plasma membrane, enabling the 
admission of glucose into the adipose and muscle tissues.   
 
Insulin, secreted from the pancreas is released into the portal vein were it is taken up by the 
liver exerting profound metabolic effects [27]. In the liver, glucose uptake is increased 
intensely because of the amplified activity of the enzymes glucokinase, phosphofructokinase-
I (PFK-l), and pyruvate kinase (PK), the main regulatory enzymes of glycolysis. Glucokinase 
(GK) acts as a glucose sensor by equipping insulin-secreting cells to connect to changes in 
glycolytic flux. As the blood glucose concentration is high, insulin secretion is initiated 
triggering glucose to enter the cell. The phosphorylation of glucose by GK to form glucose-6-
phosphate (G6P) leads to a decrease in blood glucose levels. Additionally, due to the 
incapability of G6P to be transported, it is retained in the hepatocytes acting as a precursor for 
glycogen synthesis. Following glucose phosphorylation, fructose-6-phosphate (F6P) is 
generated into fructose-1,6-biphosphate (F1,6P2) by PKF-1. The enzyme PKF-1 is activated by 
increased levels of adenosine monophosphate (AMP) and fructose 2, 6 bisphosphate (F2,6P2). 
The generation of F2,6P2 is considered as a regulatory step of glycolysis controlled by the 
enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (6PFK2/FBPase2). The last 
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rate limiting step in glycolysis involves the enzyme pyruvate kinase (PK) which is activated 
by increased levels of F1,6P2. In this step phosphoenolpyruvate is generated into pyruvate. 
These events lead to diminished blood glucose levels and increased glycogen storage. 
However, in excessive hepatic glucose production hyperglycaemia may result [28]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: The metabolism of glucose in fasted and fed states. [28] G-6P: glucose-6-
phosphate, F-6-P: Fructose 6-phosphate, 6PFK1: 6-phosphofructo-1-kinase, FBPase: fructose-
1,6-bisphosphatase, F2,6P2: fructose 2, 6 bisphosphate, IRS-2: Insulin receptor substrate 2, PI: 
Phosphoinositide, cAMP: Cyclic adenosine monophosphate, PKA: Phosphofructokinase. 
 
2.4 Pathophysiology of Hyperglycaemia 
 
Hyperglycaemia is a condition due to inadequate insulin for the regulation of blood glucose 
levels, maintaining the balance between insulin secretion and insulin action [29]. At normal, 
the pancreatic β-cell adapts to insulin action variations, as insulin sensitivity increases its 
secretion increases (vice versa)  [30]. Figure 1.5 elucidates the relation between β-cell function 
and insulin sensitivity at normal. As insulin action decreases, the body attempts to compensate 
by inducing β-cell function [29]. However, β-cell function becomes inadequate resulting in a 
dysfunction which causes elevated blood glucose levels, thus  negatively affecting insulin 
sensitivity resulting in hyperglycaemia [29, 30].  Prolonged hyperglycaemia produces toxic 
glucose levels which affects the polyol pathway, PKC activation,  hexosamine pathway, 
glucose autoxidation, methylglyoxal pathway, methylglyoxal formation and glycation, and 
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oxidative phosphorylation [31]. These pathways  lead to oxygen free radical production 
upsurge resulting in the formation of  chronic oxidative stress [32, 33]. Which subsequently 
damages enzymes and cellular organelles, induces lipid peroxidation, and the development of 
insulin resistance [34]. These consequences stimulate the development of the disease DM [35, 
36].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: The relation between insulin sensitivity and β-cell function. [29] Normal 
glucose tolerance (NGT), impaired glucose tolerance (IGT) and type 2 diabetes (T2DM) 
 
2.5 Diagnosis of Diabetes Mellitus 
 
According to the Society for Endocrinology, Metabolism and Diabetes of South Africa 
(SEMDSA), the standard criteria for the diagnosis of DM, to eliminate diabetes a fasting blood 
glucose level of <5.6mmol/L , for at risk individuals 6.0 to 6.9 mmol/L and for a diabetic 
individual >7.0mmol/L [37]. The associated symptoms include polyphagia, polydipsia, 
polyuria and weight loss [16]. Furthermore, to determine glucose tolerance, an oral glucose 
tolerance test is used (140-199 mg/dL of glucose after a 75g glucose intake) or diabetes 
(glucose >200mg after 2 hours) [38]. 
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Table 2.1: Diagnostic criteria of Diabetes Mellitus [29] 
 
 
2.6 Classification of Diabetes Mellitus  
 
In 1997, DM classification was established by the Expert Committee. It is a disorder with 
multifactorial aetiologies categorized into two main groups Type 1 and Type 2, and gestational 
diabetes as a third type [30].  
 
2.6.1 Type 1 Diabetes Mellitus 
 
Type 1 diabetes mellitus (T1DM) is identified as insulin-dependent diabetes mellitus (IDDM), 
also known as Juvenile type as it occurs in children and young adults. IDDM is characterized 
by the immune mediated pancreatic destruction of beta cells leading to the loss of insulin 
production. This condition accounts for approximately 5-10% of diabetes [18].  The deficiency 
of insulin leads to ketoacidosis and death if untreated [30]. Autoimmune disease is the most 
common form of IDDM whereby beta cells are selectively destroyed [30]. 
 
 
 
 
 
 
 Glucose concentration in venous plasma (mmol/L) 
Diabetes mellitus 
Impaired glucose tolerance 
 
Impaired fasting glucose 
 
 
 
Glucose load=75g glucose orally 
Fasting ≥7 or 2-h post glucose load  ≥11.1 
Fasting (if measured) <7.0 and 2-h post glucose load ≥ 
7.8 and <11.1 
Fasting ≥6.1 and <7.0 and 2h post glucose load ( if 
measured) <7.8 
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2.6.1.1 Pathogenic factors of Type 1 Diabetes Mellitus 
2.6.1.1.1 Genetic Predisposition 
 
Type 1 diabetes is a disorder that involves countless genes. It has been established that there 
are two approaches to track record of the natural history of T1DM. Firstly, the risk of children 
developing T1DM is whether the sibling (8%), father (5%) or mother (3%) has the disorder 
[39]. Secondly, T1DM is associated with alleles including HLA-D antigens, HLA class II DR3 
and DR4. The combination of DR3 and DR4 alleles is associated with an increased risk for this 
condition [40].   
 
2.6.1.1.2 Environmental Factors 
2.6.1.1.2.1 Infections 
 
Viral infections have been reported to be a potential cause of T1DM in case reports, 
seroepidemiological studies and early ecological reports. A number of viruses have been 
implicated, particularly enteroviruses [41]. In the presence of viruses, the injured pancreas 
experiences intense inflammation, destroying the β-cells and the surrounding exocrine 
pancreatic tissue. Recent studies have associated the occurrence of T1DM following 
enterovirus epidemics by the recognition of enteroviral RNA in the blood and the expression 
of viral capsid protein VP1 in the islets of T1DM patients [42].  
 
2.6.1.1.2.2 Nutrition 
2.6.1.1.2.2.1 Cow’s milk proteins 
 
The hypothesis of “cow’s milk and T1DM” has been questioned for more than 15 years. In 
vivo studies have verified deleterious effects of proteins from cow’s milk in the progression of 
T1DM. These proteins include bovine serum albumin and b-lactoglobulin which have been 
observed in diagnosed patients with enhanced humoral and cellular responses to cow’s milk 
[43]. 
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2.6.1.1.2.2.2 Vitamin D 
 
The deficiency of vitamin D in infancy increases the possibility of T1DM, especially in 
countries located far away from the equator. Therefore, vitamin D supplementation is required 
daily in the infant, to reduce the possibility of developing T1DM [44]. The protective factor of 
vitamin D is due to its active role in regulating the immune system and the metabolic pathways 
related to diabetes [41].  
 
2.6.1.1.2.3 Autoimmunity 
 
Autoimmunity in T1DM is a disease initiated by genetic susceptibility when interacting with 
environmental factors such as viruses and exposure to parasites/bacteria to cause the immune-
mediated process. This succeeds to autoimmunity leading to pancreatic β- cell destruction [45]. 
Autoantibodies often expressed first are insulin autoantibodies which occur particularly in 
young children. These autoantibodies may exist for years before the onset of diabetes [46]. 
Throughout this phase, the secretion of insulin is reduced, developing at quite an adaptable rate 
towards diabetes [45]. 
  
2.6.1.1.2.4 Cytokines 
 
Cytokines are proteins secreted and released by certain immune system cells which have an 
effect on the communication and interaction between cells. Cytokines include interferons, 
lymphokines, chemokines, interleukins and tumor necrosis factors. These respond to immune 
responses, infections, trauma and inflammation  [47]. In the instigation of T1DM, infiltrated 
macrophages during islet injury discharge proinflammatory cytokines such as tumour necrosis 
factor α (TNFα) and interleukin-1β (IL-1β) which attract immune cells such as T lymphocytes. 
β –cells specific antigens in the T cells are activated, infiltrating the exacerbated islets and 
attack the β-cells. Thus leading to the inability to release insulin with increased blood glucose 
levels, resulting in the pathogenesis of T1DM [48].  
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2.6.2 Type 2 Diabetes Mellitus 
 
Type 2 diabetes mellitus (T2DM) is identified as non-insulin dependent diabetes mellitus 
(NIDDM), accounting for 90-95% of DM [18, 49]. This disorder occurs among the elderly 
known as “Adult Type” [3], however over the years it has been exhibited in younger individuals 
referenced as maturity-onset diabetes of the young (MODY) [50]. This form of diabetes 
signifies disordered metabolism of proteins, carbohydrates and fat  [30] which is triggered by 
insulin deficiency and reduced sensitivity of insulin to the target tissues [9, 30]. 
Hyperinsulinism is a condition that prevails due to these defects [51]. There are probably many 
different causes of T2DM, however obesity and lifestyle appear to be the triggering factors in 
its pathogenesis, in other cases genetic predisposition is also intricate [30]. 
 
2.6.2.1 Pathogenic factors of Type 2 Diabetes Mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Illustrates the pathological features of type 2 diabetes [51] 
 
 
2.6.2.1.1 Genetic Predisposition Factors 
 
A family history with a positive T2DM increases the risk of developing this disease [29]. A 
study on identical twins in the United Kingdom revealed a genetic link of 100% concordance 
rate for T2DM [51]. The genetic basis of diabetes discovered thus far includes Wolframs 
syndrome, mitochondrial genome defects, MODY syndromes, unusual disorders of extreme 
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insulin resistance and obesity [51]. Genetic insight has been elusive, genes that have been 
identified to underlie T2DM include calpain-10 [51], ABCC8, KCNJ11 [52], SLC30A8, 
JAZF1, TCF7L2 ,PPARG, NOTCH2, WFSI and LGF2BP2 [16]. 
 
2.6.2.1.2 Environmental Factors 
 
The environmental factors associated with T2DM are nutrition and physical activity [30, 51]. 
Additional calorie intake, high fat consumption and lack of physical activity account for these 
factors leading to obesity and insulin resistance [30]. Deteriorating insulin resistance and the 
impairment of β-cell function negatively affect the glucose homeostasis system [51]. Therefore 
increasing the risk of the progression of hyperglycaemia [30, 51]. Furthermore, pharmalogical 
drugs including diuretics and phenytoin negatively affect glucose metabolism adding to the 
development of hyperglycaemia [38]. 
 
2.6.3 Gestational Diabetes 
 
Gestational diabetes mellitus (GDM) is distinguished as impaired glucose intolerance 
identified during pregnancy. It develops during the third trimester of pregnancy [30] . This 
condition affects approximately 7% of pregnancies causing complications which result in more 
than 200 000 cases annually. The risk of developing T2DM is more frequent in women with 
prior GDM [53].  The incidence of fasting hyperglycaemia >105mg/dl in GDM is associated 
with foetal death. The management of GDM is usually by diet, in some cases insulin therapy 
is recommended [54].  
 
2.6.4 Complications of Diabetes Mellitus 
 
Diabetes mellitus has various forms of complications which are either macrovascular or 
microvascular [16]. These often result in kidney failure, amputations, fractures, frailty, 
depression [55] and premature death due to the late recognition and insidious progression, 
particularly in low socio-economic countries [16]. Macrovascular diseases include diabetic 
ketoacidosis [56], coronary artery disease (CAD), cerebrovascular disease (CVD) or peripheral 
arterial disease (PAD) [57]. Whereas, microvascular include retinopathy, neuropathy and 
nephropathy [56], macrovascular diseases occur due to damage of large blood vessels (veins 
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and blood vessels arteries) and microvascular diseases are caused by the damage of small blood 
vessels [31]. 
 
2.6.4.1 Macrovascular Diseases 
2.6.4.1.1 Diabetic Ketoacidosis 
 
Diabetic ketoacidosis is a metabolic disorder as a resultant of insulin deficiency from new onset 
diabetes. Deficiency of insulin elevates counter regulatory hormones (cortisol, catecholamines 
and glucagon). The capability of the cells to use glucose is deprived causing the body to rely 
on burning fat for energy and producing ketones which accumulate rapidly. Proteins and 
glycogen are broken-down to form glucose.  Thus, hyperglycaemia develops from these 
factors, causing a hyperosmolar state, metabolic acidosis and osmotic diuresis [58]. 
 
2.6.4.1.2 Coronary Artery Disease 
 
Type 2 diabetes mellitus has a strong distinctive association with CAD. The risk factors in 
diabetic patients related with the development of CAD include insulin resistance, dyslipdemia 
and hyperglycaemia, which result in endothelial cell, impaired platelet function, vascular 
smooth muscle dysfunction and abnormal coagulation [59]. 
 
2.6.4.2 Microvascular Diseases 
2.6.4.2.1 Retinopathy 
 
Diabetic retinopathy (DR), a microvascular complication affecting the retinal vasculature 
which eventually leads to visual impairment and blindness [60]. In South Africa the prevalence 
of DR is projected between 5% and 10% [61]. The risk factors for the progression of DR 
involve prolonged period of diabetes and reduced glycaemic and blood pressure management 
[62]. The phenomena contributing to pathophysiology of the retinal vasculature destruction 
include PKC activation, oxidative stress, accumulation of glycation end products and polyols 
[63]. 
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2.6.4.2.2 Nephropathy 
 
Diabetic nephropathy (DN) is a microvascular complication which causes destruction to 
capillaries of the kidneys [31]. It is distinguished by the accumulation of proteinuria > 500mg 
in 24 hours [36]. In Africa the prevalence of DN ranges from 32-57% [64], affecting one patient 
out of three with T2DM, developing from end-stage renal disease [9]. Studies have identified 
numerous risk factors related to the progression of DN including high levels of insulin 
resistance, elevated levels of blood pressure and glycosylated haemoglobin [65].   
 
2.6.4.2.2 Neuropathy 
 
Diabetic neuropathy is long-term complication affecting almost half of diabetic patients [66-
68]. The pathogenesis of this disorder is unknown therefore various studies have tried to 
elucidate its mechanism [67]. These numerous hypotheses include advanced glycation end 
products, protein kinase C,  cytokines, polyol, aldose reductase and reactive oxygen species 
[67]. This disorder has various symptoms such as burning, “pins and needles”, crawling, itching 
[66], stabbing and unpleasant electric shock [68].Uncontrolled diabetes can result in severe 
macroangiopathies as well as outcomes such as ictus and stroke [66]. 
 
2.7 The management of Diabetes Mellitus 
2.7.1 Exercise 
 
Glucose is an essential fuel for endurance exercise in humans. Muscle contraction is an 
effective stimulus of glucose uptake in skeletal muscle during exercise [69]. The contraction 
occurs by facilitated diffusion which is reliant on GLUT4 in an insulin independent manner, 
resulting in glucose uptake [70]. The activation of  AMPK has been suggested to promote 
glucose uptake during exercise [71]. Recent studies in vivo have shown that contraction 
stimulated glucose disposal is not only mediated by AMPK, other signal intermediates 
suggested include calcium, nitric oxide, bradykinin, and the Akt substrate, AS160 [72]. In type 
2 diabetic individuals, exercise reduces circulating blood glucose concentrations and decreases 
the occurrence of hyperglycaemic episodes throughout the day [73]. This therefore increases 
insulin sensitivity in the body which lasts up to 48 hours [73]. Prolonged exercise is required, 
as inactivity increases the risk of complications [74]. Exercise affects fuel metabolism by 
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shifting from the reliance of free fatty acids to a combination of glucose, fat and muscle 
glycogen [74]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: The translocation of glucose transporter proteins (GLUT4). [72] GLUT4 can 
be translocated to the cell membrane by muscle contraction. Contractions activate a variety of 
proteins that may be associated in the signalling mechanism of exercise (i.e. AMPK, nitric 
oxide, calcium, bradykinin, AS160 and ROS).  
 
2.7.2 Diet 
 
Diabetes is a dietary related disorder, calorie-dense, nutrient depleted and highly processed diet 
leads to exaggerated blood glucose levels. It has been revealed that diabetic patients fail to 
control their dietary behaviour which is problematic [75]. The use of dietary fibres delays 
glucose diffusion, efficiently absorbs glucose and obstructs the action of α- amylase, resulting 
in depressed blood glucose levels [3]. Obesity is a condition arising from chronic ingestion of 
calories in surplus of the required needs. It results in excessive growth of adipose tissue. This 
condition has been linked to T2DM, with regards to epidemiological data [76]. Weight loss in 
obese diabetic patients is a significant component in the management of diabetes; it positively 
affects blood pressure, cholesterol and blood glucose levels. A well balanced diet can 
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accomplish weight loss. However, probable side effects may occur in patients adhering to a 
diet with low carbohydrates, such as headaches, constipation and hypoglycaemia [77]. The 
ability of AMPK to switch on catabolic pathways suggests that kinase activators can be 
effective agents in treating obesity. Thus, reducing the risk of the development of T2DM. The 
reduction of plasma glucose can occur via the activation of AMPK by inhibiting 
gluconeogenesis enzymes expression in the liver  or by increasing uptake of glucose by muscle 
and other tissues [78]. 
 
2.7.3 Insulin Therapy 
 
Insulin has become the basis for the treatment of diabetes since its discovery in 1922. Insulin 
therapy suppresses ketogenesis, restores normoglycemia, delays or arrests diabetic 
complications [79]. Insulin delivery methods include using syringes, insulin pens and 
subcutaneous insulin infusion [80]. The use of insulin injections may cause weight loss or gain. 
Insulin can cause hypokalemia by driving potassium into the cell. The combination of insulin 
injection and other drugs such as thiazolidinedione’s can result in cardiac failure. Constituents 
of insulin preparation can cause allergy [77]. 
 
2.7.4 Pharmacological treatments and their limitations 
 
Diabetes has a long progression and grave complications often resulting especially in 
developing countries due to reconstruction of lifestyle. If exercise and diet are not effective, 
pharmacological agents are prescribed to the patients [3]. These medications are mostly 
biochemical or chemical agents [18], which increases  secretion of insulin  by either acting on 
pancreatic β-cells (metaglinides and sulphonylureas) or enhancing the peripheral sensitivity to 
insulin (thiazolidinediones and biguanides). Furthermore, agents with inhibitory effect on 
intestinal α-glucosidase are recommended, these are able to decrease postprandial 
hyperglycaemia [8].  
 
2.7.4.1 Biguanides 
 
Biguanides are drugs reducing the hepatic glucose production [38]. Metformin is a biguanide  
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drug derived from the plant Galega officinalis, used as the first line of treatment for T2DM 
[81]. Studies have reported that treatment with metformin in controlling glucose has reduced 
the risk of diabetes related complications and mortality in diabetic obese patients, and also 
related to less hypoglycaemic attacks when compared to other antidiabetic drugs [82]. The key 
function of metformin is to reduce hepatic glucose production by inhibiting the hepatic glucose 
output [29, 81]. Metformin also improves cardiovascular safety and peripheral insulin 
sensitivity [81]. The mechanism of action of metformin includes AMPK activation in the 
hepatocytes [83], stimulated by the inhibitory effect of the drug on the respiratory chain 
complex I [82] and by blocking adenylyl cyclase via the inhibitory effect on glucagon-induced 
cAMP production [84]. However metformin has side effects including nausea, weight gain, 
diarrhoea, abdominal discomfort [38] and lactic acidosis [81].   
 
2.7.4.2 Sulfonylureas  
 
Sulfonylureas increases the production of insulin by stimulating pancreatic beta cells [3]. In 
the ATP-sensitive potassium (KATP) channel these bind to SUR subunit therefore closing the 
channel [85], resulting in enhanced insulin secretion[29]. However, the closure of the channels 
is not absolute, consequently the inhibition of the high-affinity sulfonylureas is not complete 
[85]. Sulfonylureas in the liver limits gluconeogenesis by decreasing the metabolism of lipids 
and reducing the clearance of insulin. These agents are grouped in to two categories:  first-
generation agents (tolbutamide, chlorpropamide and tolazamide) and second-generation agents 
(glyburide, glipizide and glimepiride) [77]. These drugs proliferate the risk of weight gain [81], 
cardiovascular disease and hypoglycaemia [86].   
 
2.7.4.3 Non-sulfonylurea secretagogues 
 
Non-sulfonylurea secretagogues are agents acting on the KATP channel in the pancreas, 
stimulating the beta cells to release insulin. These are similar to sulfonylureas however act at 
different binding sites [16]. These include nateglinide and repaglinide [81]. The action of 
meglitinide has a short duration and rapid onset hence it has a lower risk of hyperglycaemia 
[16]. 
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2.7.4.4 Sodium-Glucose co-Transporters (SGLT2) Inhibitors 
 
SGLT2 inhibitors are a class of antidiabetics which act by inhibiting renal glucose reabsorption 
in the kidneys. These are the main cotransporters for tubular glucose reuptake, in abundance of 
SGLT2 cotransporter’s glycosuria arises. Therefore, inhibitors of this activity reduce blood 
glucose levels by blocking glucose reabsorption from the renal tubule. Several trails have 
investigated the safety and efficacy of these inhibitors, displaying body weight reduction, 
amended glucose control and blood pressure with a low risk of hyperglycaemia [87]. 
 
2.7.4.5 Incretin Mimetics 
 
Glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic peptide are the main 
incretin hormones. These are secreted from the small intestine endocrine cells in the epithelium, 
stimulated by induced concentration of glucose in the intestinal tract. Incretins promotes insulin 
secretion by stimulating the pancreatic β-cells but inhibit α-cells from discharging glucagon. 
Both these hormones are rapidly degraded by dipeptidyl peptidase (DPP)-4 which is a serine 
protease. In vivo studies have recognised the importance of DPP-4 as a determining factor of 
incretin concentrations because DPP-4 inhibitors avert the breakdown of glucose-dependent 
insulinotropic peptide and GLP-1. Thus, there are 2 classes of incretin drugs which have been 
developed: DPP-4 inhibitor and GLP-1 analogue [88]. 
 
2.7.4.6 Glucagon-like peptide-1 (GLP-1) Receptor Agonists 
 
GLP-1 is a hormone that increases insulin secretion, decreases glucagon secretion and 
maintains blood glucose levels. The excretion of GLP-1 is often reduced in diabetic patients. 
GLP-1 receptor agonists currently available include liraglutide and exenatide. These agents 
exhibit augmented resistance to enzymatic degradation by DPP4 [89]. 
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2.7.4.7 Dipeptidyl peptidase 4 (DPP-4) inhibitors 
 
In managing T2DM by inhibiting DDP-4, it prevents the inactivation of GLP-1. Therefore, 
increasing the secretion of insulin and reducing glucagon secretion, in turn lowering blood 
glucose levels [90]. DDP-4 inhibitors include vidagliptin, linagliptin, sitagliptin, saxagliptin 
and alogliptin [77]. 
 
2.7.4.8 Thiazolidinedione’s 
 
Thiazolidinedione’s improve insulin sensitivity to the muscles and other tissues [3, 81]. These 
agents act on peroxisome proliferator-activated receptor alpha (PPARY), causing it to bind to 
9-cis retinoic acid receptor. The binding regulates genetic transcription and translation of 
proteins involved in glucose and lipid metabolism[91]. Thiazolidinedione’s include 
pioglitazone and rosiglitazone [81]. The use of rosiglitazone is restricted due to the increased 
risk of cardiovascular complications [16]. Pioglitazone can be used in renal impairment cases, 
as it is not associated with hypoglycaemia however it raises concerns regarding fluid retention, 
peripheral edema and risk fracture in women [16]. Side effects of thiazolidinedione include 
weight gain and edema [81]. 
 
2.7.4.9 α- Glucosidase inhibitors 
 
α-Glucosidase inhibitors interrupt the carbohydrate absorption from the gastrointestinal tract 
[3]. These include acarbose, voglibose and miglitol. α-Glucosidase inhibitors are mostly 
effective for postprandial hyperglycaemia [16] and also modulating the incretin hormones i.e. 
increasing endogenous glucagon-like peptide-1 or replicate the action of GLP-1. Side effects 
include abdominal pain, diarrhoea and flatulence [81]. 
 
2.7.5 Supplements 
2.7.5.1 Vanadium 
 
Vanadium has not been recognized as an essential nutrient; it exists in vanadyl and vanadate 
forms. It has been shown in animal models to facilitate amino acid, lipid and glucose 
metabolism, the uptake and improvement of insulin sensitivity. In humans, it improves glucose 
oxidation, hepatic glucose output and glycogen synthesis. Vanadium affects numerous points 
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in the pathway of insulin signalling and may result in the upregulation of the insulin receptor, 
leading to increased tyrosine serine threonine kinase activity, inhibition of hepatic 
gluconeogenesis and improved synthesis of glycogen. Oral supplementation of vanadium may 
cause vomiting, nausea, flatulence, cramping and diarrhoea [92]. 
 
2.7.5.2 Chromium 
 
Chromium is a trace element that is necessary for the regulation of normal glucose metabolism. 
A deficiency of chromium results in impaired glucose tolerance which can be improved by 
adding chromium to the diet. Chromium has been reported to decrease fasting glucose levels, 
decrease insulin levels, and reducing total triglycerides and cholesterol whereas HDL 
cholesterol being increased. This element performs by enhancing insulin actions through an 
increase in the sum of insulin receptors and increased binding of insulin to the insulin receptors. 
Studies in vitro have suggested that chromium picolinate at high doses may result in 
chromosomal damage at increased rates. Chromium at high doses has been shown to cause 
hepatic and renal toxicity, psychiatric disorders, hypoglycaemia, rhabdomylosis, competes 
with iron for transport on transferrin and decreases zinc absorption [92]. 
 
2.7.5.3 Nicotinamine 
 
Vitamin B3 occurs in two forms, nicotinamide and nicotinic acide. Nicotinamide adenine 
dinucleotide NAD and NAD phosphate are the active coenzyme forms responsible for the 
functions of numerous enzymes and standard lipid, protein and carbohydrate metabolism. 
Studies suggest that nicotinamide acts as a defensive mechanism for the pancreatic β-cell 
against autoimmune destruction. However, side effects associated with nicotinamine include 
dizziness, nausea, heartburn, skin reactions, vomitting, sore mouth, fatigue and hepatotoxicity 
[92]. 
 
2.7.5.4 Magnesium 
 
Magnesium is a mineral that acts as a cofactor for more than 300 enzymes. A deficiency of 
magnesium is connected to insulin resistance, complications of diabetes, dyslipidemia and 
glucose intolerance. However, the mechanism by which magnesium affects these 
22 
 
phenomenons is unknown. High doses of magnesium may cause nausea, headaches, central 
nervous system disorders, altered cardiac function and death [92].  
 
2.7.5.5 Vitamin E 
 
Vitamin E is a vital fat-soluble vitamin which acts as an antioxidant. Low levels of Vitamin E 
are linked to increased occurrences of diabetes, diabetic people are suggested to have reduced 
levels of antioxidants. Vitamin E functions to counteract free radical species developed during 
cellular metabolism, shielding cellular membranes and lipoproteins. It may also treat and 
prevent diabetes complications such as neuropathy and nephropathy. Vitamin E has been 
shown to cause increased risk of haemorrhage stroke [92]. 
 
2.8 Medicinal Plants in managing Diabetes Mellitus 
 
Diabetes treatment requires immense quantities of resources including physical training, diets 
and medicines in all countries [18]. Conventional drugs also have adverse effects such as lactic 
acid intoxication, gastrointestinal upset and hypoglycaemia [18]. However, traditional 
medicine has been perceived to have minimal side effects in scientific research and moderately 
low costs [2]. Plants have been an effective source of medication against numerous diseases 
since ancient times [93]. Asia and Africa have a profound culture on the use of traditional 
remedies [94]. It is approximated that 80 percent of South Africans rely on medicinal plants 
for their health care needs [95]. These medications have been recognized as an alternative 
measure in managing diabetes [18]. Hypoglycaemic action of medicinal plants has been 
established in in vivo and in vitro studies [3]. Numerous compounds have been identified and 
isolated from plants used as antidiabetics [96]. 
 
2.8.1 Plants used in the management of Diabetes Mellitus 
2.8.1.1 Aloe vera 
 
Aloe vera is a plant that has been used in herbal medicine for centuries in numerous cultures. 
[97]. It is botanically called Aloe barbadenis miller, belonging to the family Asphodelaceae 
(Liliaceae) [98]. Aloe vera has been used intensively as a folk remedy in treating burns, eczema, 
wounds and psoriasis [99].  The active components of this plant are found in the rind of the 
leaves and gel [100].  Pharmacological study in streptozotocin-induced diabetic rats revealed 
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the significant reduction in blood glucose after ethanolic extract administration of Aloe vera 
gel [97, 100]. Hypoglycaemic activity has also been investigated in alloxan-diabetic rats [99]. 
 
2.8.1.2 Panax ginseng 
 
Panax ginseng is a herbal plant from the family Araliaceae [101], native to Korea and China 
with active agents known as ginsenosides which are triterpene saponins [101, 102]. It is used 
traditionally for hypotonia, insomnia, neuralgia, neurasthenia, depression, as a stimulant, 
stomachic and  diuretic [99]. The root has been used as a tonic without any side effects for 
years [103]. A pharmacological study by Chung et al (2016), revealed a reduction in 
hyperlipidaemia, body weight gain and hyperglycaemia in diabetic animals receiving ginseng 
in their diet [102]. In addition, P. ginseng extract has been reported to increase the number of 
insulin receptors in the bone marrow and decrease the number of glucocorticoid receptors in 
the rat brain. These parameters contribute to the antidiabetic action of P. ginseng [104].  
 
2.8.1.3 Green Tea 
 
Green tea is formed by enzymatic inactivation of Camellia sinensis leaves [105], it is the most 
consumed beverage [106]. Botanical evidence suggests that the cultivation of green tea 
occurred in China and India originally [107]. It is abundant in catechins, mainly 
epigallocatechin gallate (EGCG), which has been suggested to have numerous beneficial health 
effects [106]. Studies in vitro have suggested that EGCG helps in preventing hyperglycaemia 
by improving the activity of insulin and perchance by averting damage to β-cells [106]. This 
catechin has been shown to inhibit differentiation in 3T3-L1 cells and adipocyte proliferation, 
escalate fat oxidation and increase GLUT4 expression in adipose tissue of an animal model. 
[108].  
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2.8.2 Class of Antidiabetic Compounds 
2.8.2.1 Flavonoids 
 
Flavonoids are dispersed in plants as naturally occurring phenolic compounds [109]. These 
have anti-oxidant properties as they possess aromatic hydroxyl groups [109]. Flavonoids have 
been extensively studied due to their beneficial properties in relieving cardiovascular disease 
[110]. These compounds overturn the glucose level, decrease plasma triglycerides and 
cholesterol, and induce hepatic glucokinase activity hence increasing the release of insulin from 
the pancreatic islets [3].  
 
Figure 2.8: Selected flavonoids [111] 
 
2.8.2.2 Alkaloids 
 
Alkaloids are secondary compounds found in several sources including fungi, animals and 
plants [112]. These compounds have a heterocyclic nitrogen, acting as a H-acceptor and a  H-
donor [113]. This capability improves the probability of hydrogen bonds, which are critical for 
acting as therapeutic drugs or bioactive compounds [113]. Alkaloids cause the inhibition of α-
glucosidase and reduce transportation of glucose through the intestinal epithelium [3]. 
Berberine, palmatine, coptisine, and jatrorrhizine are alkaloids that have been confirmed to 
possess beneficial effects on diabetes and its complications [114].    
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               Jatrorrhizine                                                                         Coptisine 
 
Figure 2.9: Chemical structures of Alkaloids with antidiabetic effect. [115] 
   
2.8.2.3 Saponins 
 
Saponins are naturally produced in plants as glycosides [116]. These compounds contain a 
sugar moiety usually galactose, glucose, glucuronic acid or methylpentose, linked 
glycosidically to hydrophobic aglycone such as steroid or triterpenoid (fig 1.5) [116]. Saponins 
are able to stimulate insulin discharge, blocking glucose formation in the bloodstream [3].  
 
 
 
Figure 2.10: Chemical structures of selected Saponins [117] 
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2.9 Selected plant for this study 
2.9.1 Warburgia salutaris 
 
The genus Warburgia belongs to the family Canellaceae, comprising of nine species. The 
species W. salutaris (Bertol. f.) Chiov. is distributed in southern Africa, as a rare constituent in 
Swaziland, Mozambique, Zimbabwe and South Africa [118]. W. salutaris is commonly known 
as the ‘pepper-bark’ due to its peppery taste of the leaves and bark [119, 120], also known as  
‘mulanga’ in Venda and ‘xibaha’ in Tsonga [119] 
 
2.9.1.1 Botanical description 
 
W. salutaris is a medium sized evergreen tree, about 5 to 10 m in height with a stem diameter 
reaching 30 cm (Fig 2.16). Its trunk is short with an erect, dense canopy. The bark at a young 
phase is smooth, white to light grey, once it matures it becomes brown. The inner bark is 
reddish brown in appearance, bitter with a pungent and peppery smell. The leaves have a 
burning, bitter and aromatic taste when crumpled. The leaves are alternate, simple, dark green 
above, paler green below and glossy. The flowers are white to greenish in appearance, bisexual, 
small, solitary and axillary. The flowers grow into round, oval berries, dark green turning 
purple when ripe and narrowed towards the base. The fruits have a leathery surface, enclosed 
with glands comprising two or more seeds, during maturation they turn black from purple 
[119].            
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Figure 2.11: Warburgia salutaris: Mature specimen (a), foliage (b), fruit (c) and bark (d). 
[121] 
 
2.9.1.2 Phytochemistry 
 
Studies have reported numerous drimane sesquiterpenoid compounds isolated from the leaves 
and bark of W. salutaris consisting of  biological activities such as antibacterial, antifeedant, 
antifungal, anticomplemental, phytoyoxic, cytotoxic and molluscicidal activities [122]. These 
compounds include warburganal, salutarisolide, polygodial, muzigadial, ugandensidial, 
isopolygodial and mukaadial[120]. 
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2.9.1.3 Medicinal uses 
 
W. salutaris has been used ethnopharmacologically for dermatological pathologies such as 
sores, urethral inflammation and penile irritation. The powdered bark is applied to sores and 
inflamed areas. Ointments produced from pounded stalks and leaves, in concoction with the 
bark and fat, are used for skin irritations and inflammation [122]. A decoction of the bark is 
usually administered for influenza, colds, sinus [118], as an emetic to clear patches in the lungs 
and chest infections productive of purulent sputum [123]. 
 
2.10 Aim and objectives 
2.10.1 Aim 
 
To biologically screen the antidiabetic potential of the plant W. salutaris. 
 
2.10.2 Objectives 
 
 To collect the plant material and prepare a voucher specimen 
 To isolate, purify and characterize bioactive compound(s) from the plant using 
chromatographic and spectroscopic techniques. 
 To investigate the cytotoxicity of the isolated compound(s). 
 To determine in vitro the effectiveness of the isolated compound(s) on glucose uptake. 
 To investigate in vitro the inhibitory action of the crude extract and isolated 
compound(s) on digestive enzymes. 
 To determine in vitro the antioxidant ability of the crude extract and isolated 
compound(s).  
 To determine the in vivo antidiabetic activity of the crude extract and isolated 
compound(s). 
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Chapter 3 
Materials and methods 
 
This chapter describes briefly all the methodologies carried out in this study. A list of the 
significant chemicals, reagents and equipment used in this study is also given.  Information 
pertaining the reagents preparation and details of the methodologies are in Appendix A and B. 
 
3.1 Materials 
 
Chemicals applied in this study were of analytic grade as indicated: Dichloromethane, hexane, 
ethyl acetate, tween 20, sulphuric acid, ascorbic acid, nutrient agar, potassium dihydrogen 
orthophosphate, di-potassium hydrogen orthophosphate anhydrous, sodium citrate, sodium 
chloride, sodium hydrogen phosphate, citric acid sodium dihydrogen phosphate (Merck 
chemicals (PTY) LTD, Johannesburg South Africa), streptozotocin (Inqaba Biotechnical 
Industries (Pty) Ltd, Pretoria South Africa), acarbose, starch, alpha glucosidase, P-
Nitrophenyl-α-D-glucopyranoside, DNSA,  1,1-diphenyl-2- picrylhydrazyl (Sigma-Aldrich 
Co., Ltd Steinheim, Germany).  
 
Equipment: 
Grinder- Hippo Mills (AC Trading, South Africa) 
Rotary evaporator (Heidolph Instruments GmbH & Co, Germany) 
UV Light- CL-150 Ultraviolet Fluorescence Analysis Cabinet (Spectronics Co, New York) 
Nuclear Magnetic Resonance (Bruker) 
Spectrophotometer- Biowave DNA (Biochrome, Cambridge UK) 
Spectrostar Nano Plate reader (MBG LABTECH, Germany) 
Sprague Dawley rats-Biomedical research unit, University of KwaZulu-Natal 
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3.2 Methods 
3.2.1 Plant collection and preparation 
 
The plant species used in the present study, Warburgia salutaris (Bertol. f.) Chiov. (stembark) 
was collected from the Botanical garden of the University of KwaZulu-Natal, Pietermaritzburg 
Campus, KwaZulu-Natal, South Africa (29° 37′ 30′′ S, 30° 24′ 14′′ E), in March 2017. The 
plant was authenticated and reconfirmed by Mrs Alison Young (horticulturist) and voucher 
specimen (NU0043932) was obtained at the UKZN’s Bews Herbarium (PMB). The plant 
material was washed and sun dried for one week, weighing 16 kg. The material was thereafter 
ground into fine powder form using a Hippo-grinder obtained from the botanical garden at 
UKZN-PMB campus and stored in a brown glass bottle. 
 
3.2.2 Extraction of crude extract 
 
The powered stembark of W. salutaris (3.9 kg) was extracted with dichloromethane (DCM) 
(1:5w/v) for three days successively. Whatman (No.1) filter paper was used to filter the extract 
and concentrated under a reduced pressure (45°C) to a minimum volume using a Heidolph 
rotary evaporator. The concentrated extract was desiccated under a fume hood overnight. The 
resultant DCM crude extract weighed 58g.  
 
3.2.3 Chromatographic analysis 
 
In this study, silica gel column chromatography (60x1000mm; Merck silica gel, 60: 0.063-
0.200mm) was performed to isolate the DCM crude extract and the eluent system used was 
hexane: ethyl acetate.  The distillation of hexane and ethyl acetate at 67°C and 77°C 
respectively was prepared preceding the analysis. The eluent ratio used was 9:1 to 8:2. In each 
column, 10g of crude extract was used with 300g silica gel.  
 
Thin layer chromatography (TLC) (silica gel 60 aluminium sheets, F254—Merck, Whitehouse 
Station, New Jersey, USA) was used to monitor the presence of a compound. The TLC spots 
were fixed with a solution made of 20% H2SO4 in methanol, heated with a hair dryer for colour 
development and visualized under Spectroline UV light (Berg Engineering & Sales, Company, 
Inc. Rolling Meadows, United States) at 254nm. The fractions were collected per 80ml and 
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accordingly combined through their TLC profiles. The retention factor value of the visualized 
compound was 0.6. The fractions were left overnight to dry under a fume hood. A white powder 
(NN-01) was obtained from the 8:2 ratio of W. salutaris.  
 
3.2.4 Structural Elucidation 
 
The structure of the compound was identified using NMR spectroscopy techniques, infrared 
(IR) and x-ray crystallography at the University of KwaZulu-Natal PMB campus Chemistry 
department. The NMR techniques conducted in this study are as follows; 1H, 13C, DEPT, 
COSY, DEPT, HSQC, NOESY and HMBC. Fillezilla 3.21.0 copyright © 2004-2016 Tim 
Kosse was used to collect the NMR data and process it into spectra. Spinworks 4.0 copyright 
©2014, Kirk Marat, University of Manitoba was used to produce the NMR spectrum (See 
Appendix C). 
 
3.3 In vitro studies 
3.3.1 Cytotoxicity Evaluation 
 
Cytotoxicity assay was determined at Nelson Mandela Metropolitan University, Department 
of Biochemistry and Microbiology. L6 cells, originally derived from skeletal muscle of rat 
were grown in DMEM supplemented with 10% FCS and subcultured by trypsinisation.  Cells 
were seeded into 96-well plates at a density of 5000 cells/well.  At approximately 80% 
confluent the medium was substituted with differentiation medium (DMEM containing 2% 
horse serum). Cells were incubated for 3-5 days to allow full differentiation. 
 
Spent culture medium was substituted with fresh medium containing the test compounds at the 
indicated concentrations and treated for 48hr.  Spent culture medium was removed and 100μl 
fix solution (10% formaldehyde in PBS) was added.  After removal of the fix solution, 100μl 
crystal violet was added and incubated at room temperature for 10min.  The crystal violet dye 
was removed and the wells washed three times with tap water and once with distilled water.  
Plates were left to dry overnight at 37°C and the bound dye solubilised by adding 200μl 10% 
acetic acid. The absorbance at 595nm was read and the cytotoxicity expressed as a percentage 
of the untreated control.   
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3.3.2 Glucose utilisation screening 
 
Glucose utilisation assay was determined at Nelson Mandela Metropolitan University, 
Department of Biochemistry and Microbiology. Cells were seeded and treated identically as 
described for the cytotoxicity assay except that after the 48hr treatment and removal of spent 
culture medium, the cells were washed once with PBS. Fifty micro-litres of 8mM glucose 
solution (DMEM medium diluted with PBS and supplemented with BSA to a final 
concentration of 0.1%) was added.  For the positive control, 1000ng insulin was added. Plates 
were returned to the incubator. After 2 hours 5μl was transferred to a new plate and 200ul 
glucose assay reagent (glucose oxidase/peroxidase colorimetric reagent) was added and 
incubated at 37° for 10min.  Absorbance was measured at 510nm. Glucose utilisation was 
calculated as the difference between the no cell control and the test sample and expressed as a 
percentage of the untreated control.  
 
3.3.3 α- Amylase inhibition assays 
 
The inhibition of α- amylase was determined according to the method described by Sathiavelu 
et al. [124]. A total of 500µl of M. acetate and crude extract at varying concentrations and 
500μl of 0.02M sodium phosphate buffer (pH 6.9 comprising 0.006M sodium chloride) 
containing α-amylase solution (0.5mg/ml) were incubated for 10 minutes at 25°C. Afterwards, 
500μl of 1% starch solution in the same buffer was added to each test tube. The reaction mixture 
was incubated for a further 10 min at 25°C. DNSA colour reagent (1 ml) was added to halt the 
reaction. The test tubes were incubated in boiling water bath for 5min and cooled to room 
temperature. 10ml dH2O was thereafter added to the mixture, followed by absorbance 
measurement at 540nm. Acarbose was used as a positive control. 
 
3.3.4 α – Glucosidase inhibition assays 
 
The inhibition of α – Glucosidase activity was done according to the assay adopted from Bajpai 
et al. [125]. Briefly, 10μL of test samples at several concentrations and 50 μL of yeast α-
glucosidase, dissolved in 100 mM phosphate buffer (pH 7.0) (containing0.2 g/L NaN3 and 2 
g/L bovine serum albumin) were mixed in 96 well micro-plate and absorbance at 595 nm was 
read at zero time with a micro-plate reader. After an incubation period of 5 min, 50 μL of P-
Nitrophenyl-α-D-glucopyranoside (5 mM) in the same buffer (pH 7.0) was used as a substrate 
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solution and incubated for a further 5 min at room temperature. 80 μL of 0.2 M sodium 
carbonate solution was added to terminate the reaction. The absorbance was read at 595 nm. 
The reaction without α-glucosidase was used as a blank, and acarbose at several concentrations 
was used as a positive control.  
 
Each experiment was conducted in triplicates and the enzymatic inhibition rate was calculated 
as follows: 
Inhibition (%) = (Control absorption-Sample absorption) x 100 
Control absorption 
 
 
3.4 Antioxidant Activity 
3.4.1 1,1-diphenyl-2- picrylhydrazyl scavenging activity 
 
1,1-diphenyl-2- picrylhydrazyl (DPPH) free radical scavenging effect of  M. acetate was 
determined by a standard method Brand-Williams et al. [126]. An aliquot of DPPH solution 
(2mg in 100 ml MeOH) was prepared and 2ml of this solution was added to 2 ml of each sample 
solution in methanol at varying concentrations. The mixtures were left for 30 min in the dark 
at room temperature. A spectrophotometer was used to measure the absorbance of each sample 
at 517 nm. The scavenging effect expressed (%) was calculated using the following formula: 
 
Scavenging effect (%) = 1- [ASample / AControl] X 100 
 
 
3.5 In Vivo Study 
3.5.1 Ethical clearance 
 
The experiments on animals were approved by the University of KwaZulu-Natal Ethics 
committee (Ref: AREC/009/017M) (See Appendix D). 
 
3.5.2 Animals 
 
In this study, male Sprague Dawley rats (200-250g) housed and bred at the University of 
KwaZulu-Natal, Westville campus, Biomedical Resource Unit were used. The animals were 
maintained under standard laboratory conditions of 12:12 h light/dark cycle and controlled 
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temperature of 24 ±1°C with relative humidity 40-60%, with water and food (Meadows, 
Pietermaritzburg, South Africa) freely available. 
 
3.5.3 Preparation of the treatment 
 
The crude extract (1.5mg/kg) and compound M. acetate (0.5, 1.5 & 2.5mg/kg) were prepared 
by thawing it in tween 20 and bringing it up to the required volume by the addition of dH2O. 
Acarbose was used as a positive control (10 mg/kg) [127]. The doses depended on the average 
weight per group.  
 
3.5.4 Induction of Diabetes Mellitus 
 
Diabetes mellitus was induced by a single intraperitoneal (i.p.) injection of streptozotocin 
(STZ; 60mg/kg) dissolved in freshly prepared cold 0.1 mol/L citrate buffer (pH 4.5). The 
animals were considered to be diabetic after one week with a blood glucose concentration ≥18 
mmol/L [128]. The blood glucose was measured from the tail vein blood using a Roche 
ACCUCHEK Aviva Nano glucometer (Basel, Switzerland). 
 
3.5.5 Experimental Design 
 
The experiment was carried out on sixty six male Sprague Dawley rats for 21 days. The animals 
were divided into two main groups (Non-Diabetic and Diabetic), with six animals in each 
subgroup. The groups were as follows:  
 
Non-Diabetic Groups Diabetic Groups 
Non-treated Non-treated 
Vehicle (Tween 20) Acarbose (10 mg/kg) 
M. acetate (0.5 mg/kg) M. acetate (0.5 mg/kg) 
M. acetate (1.5 mg/kg) M. acetate (1.5 mg/kg) 
M. acetate (2.5 mg/kg) M. acetate (2.5 mg/kg) 
 Crude Extract (1.5 mg/kg) 
 
On the commencement of the experiment, animals were placed in metabolic cages (one per 
cage) overnight. On Day 0, the baseline measurements and samples were taken (blood glucose 
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levels, food intake, water intake, weight and urine). The measurements and samples were taken 
in three day intervals before and after the treatment period, during treatment they were taken 
daily. The animals were treated orally once per day (900hr) for five sequential days (Day8-12). 
On Day 21, the animals were sacrificed, blood was collected into pre-cooled heparinised tubes 
for plasma insulin measurement and EDTA tubes for haematology parameters determination. 
Harvesting of muscle, liver, pancreas and kidneys was also done for further evaluation. The 
organs were halved, placed in 10% formalin and -70 bio freezer. 
 
The rat grimace scale [129], from the National Centre for the Replacement Refinement and 
Reduction of Animals in Research (NC3Rs), was used to evaluate whether the animals were 
suffering during the test. The grimace scale consists of five facial parameters (nose and cheek 
flattening, orbital tightening, whisker change and ear change) that were used to assess pain 
sensed by the animals. If an animal was found to be suffering, it was excluded from the 
experiment via decapitation.  
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3.5.5.1 Experimental Flow Diagram 
 
Figure 3.1: In vivo experimental flow diagram 
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3.5.6 Insulin Assay 
 
Rat Insulin Elisa Kit (Thermo ScientificTM PierceTM, USA), is an enzyme-linked 
immunosorbent assay which was used to measure rat insulin serum. The procedure was as 
follows: 100μL of each standard and sample was added into appropriate wells and incubated 
for 2.5h at room temperature (RT) on an orbital shaker. Thereafter, the solution was discarded 
and the plate was washed four times with a Wash Buffer. 100μL Biotinylated antibody was 
added and incubated at RT for 1h. The plate was washed four times, adding 100μL streptavidin-
HRP to each well and incubated at RT for 45min. The plate was washed four times, 100μL 
TMB substrate was added and incubated in the dark at RT for 30min on an orbital shaker. The 
reaction was terminated by adding 50μL of stop solution. The absorbance was read on an 
ELISA plate reader at 450nm and 550nm. 
 
3.5.7 Haematology parameters determination 
 
At the end of the experimental study period, on day 21, blood was collected by cardiac puncture 
into pre-cooled heparinised tubes for plasma insulin measurement. Blood was also collected 
into pre-cooled EDTA tubes for haematology parameters determination for measurement of 
haematology parameters (red blood cell count (RBC), haemoglobin (HBG), haematocrit 
(HCT), neutrophils (NE), basophils (BA), eosinophils (EO), monocytes (MO) and lymphocytes 
(LY). A calibrated automated Beckman Coulter haematology analyser was used (Climet 
Instruments Company, Redlands CA United States).   
 
3.6 Statistical analysis  
 
The data was expressed as means ± SEM. Statistical analysis of cytotoxicity and glucose 
utilisation was measured using Microsoft excel software, 2013. Statistical comparison of the 
differences between the means of control and experimental groups was performed with 
GraphPad Prism Software version 5.00, using two-way analysis of variance (ANOVA), 
followed by Bonferroni posttests. A value of p < 0.05 was considered significant. 
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Chapter 4 
Results 
 
Crude extract of the medicinal plant W. salutaris was screened for bioactive compounds, 
antidiabetic and antioxidant activity. The isolated compound M. acetate was also screened for 
antidiabetic and antioxidant activity. This chapter gives an overview of the findings of the 
present study. 
 
4.1 Structural Elucidation 
 
The chemical shift of the compound NN-01 (Table 4.1) was studied and it was established that 
it was a novel compound isolated from the plant W. salutaris or any other plant species. The 
compound was regarded as Mukaadial acetate (Fig 4.1). Low resolution and high resolution 
Mass spectra (MS) was determined at the University of KwaZulu-Natal PMB campus 
Chemistry department. Fig 4.2 displays the mass spectra of M. acetate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Thin layer chromatography plate presenting crude extract and Mukaadial 
acetate 
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Table 4.1: 1H- and 13C-NMR chemical shifts (δ, ppm) of M. acetate 
position δc (ppm) CHn δH (ppm) 
1 66.13 CH 5.91(t, H, J = 4.8 Hz) 
2 148.60 CH 7.01(d, H, J = 4.8 Hz) 
3 141.00 C  
4 32.56 CH 4.07 
5 41.66 C  
6 31.83 CH2  
7 17.70 CH2  
8 44.02 CH2  
9 34.00 C  
10 44.97 CH 2.06(d, H, J = 4.8 Hz) 
11 193.01 CHO 9.76 
12 201.44 CHO 9.48 
13 19.95 CH3 1.34 
14 24.75 CH3 1.17 
15 21.44 CH3 1.03 
16 170.01 COOR  
17 19.95 CH3 2.14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: X-ray structure of M. acetate 
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Figure 4.3: Single mass analysis of M. acetate 
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4.2 In vitro studies 
4.2.1 Cytotoxicity Evaluation of M. acetate 
 
The cell viability effect of M acetate was highest at 3µg/ml with a percentage of 98.4, with an 
IC50 value of 13.45µg/ml. At concentrations greater than 3µg/ml, cell viability significantly 
reduced in a dose dependant manner (p< 0.05) (Fig 4.4) 
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Figure 4.4:  Cytotoxicity of L6 cells after 48 hour treatment with M. acetate. Cytotoxicity 
was determined using crystal violet and data expressed as a percentage of the untreated control.  
*p< 0.05 
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4.2.2 Glucose utilisation screening of M. acetate 
 
M. acetate significantly (p<0.05) and dose dependently increased glucose utilisation up to 
215.18% (12.5µg/ml), however, cytotoxicity at the higher concentrations tested severely 
attenuate cellular glucose utilisation (Fig 4.5).  
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Figure 4.5:  Glucose utilisation in L6 cells after 48 hour treatment with M. acetate. 
Glucose utilisation is calculated as the difference in remaining glucose after 2hr incubation 
between the no cell control and cells with the respective treatment.  Data is expressed as a 
percentage relative to the untreated control.  *p< 0.05 
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4.2.3 Effect of M. acetate and crude extract on α- amylase inhibition  
 
α- Amylase inhibitory activity of M. acetate and crude extract was found to be in a 
concentration dependent manner. M. acetate showed inhibition of the enzyme with the highest 
value of 41.05% seen at 50µg/ml compared to the crude extract with a value of 31.22%. (Fig 
4.6). 
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Figure 4.6: Percentage α-Amylase inhibitory effect of standard compound Acarbose, M. 
acetate and crude extract. Values are presented as means. 
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4.2.4 Effect of M. acetate and crude extract on α – Glucosidase inhibition  
 
α- Glucosidase inhibitory effect of M. acetate and crude extract was executed against the 
enzyme in a dose dependent manner. M. acetate showed inhibition of the enzyme with the 
highest value of 29.61% seen at 50µg/ml compared to the crude extract with a value of 22.17%.  
(Fig 4.7).   
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Figure 4.7: Percentage α-Glucosidase inhibitory effect of standard compound Acarbose, 
M. acetate and crude extract. Values are presented as means. 
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4.2.5 Effect of M. acetate and crude extract on 1,1-diphenyl-2 picrylhydrazyl 
 
The scavenging activity of M. acetate and crude extract against DPPH was presented in a dose 
dependent manner. M. acetate displayed a scavenging effect with the highest value of 42.65% 
seen at 50µg/ml compared to the crude extract with a value of 40.97%.  (Fig 4.8).    
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Figure 4.8: Percentage DPPH inhibition activity of standard compound Ascorbic acid M. 
acetate and crude extract. Values are presented as means. 
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4.3 In Vivo Study 
4.3.1 Effect of M. acetate and crude extract on blood glucose and insulin 
concentrations 
 
M. acetate at the varying concentrations (0.5, 1.5 and 2.5mg/kg) in the non-diabetic group did 
not significantly affect the blood glucose levels, compared to the control animals (Fig 4.9 (a)). 
On Day 11 and 13, a significant (**p<0.01) reduction in blood glucose levels was presented 
by the diabetic positive control. A significant increase in blood glucose levels was presented 
by M. acetate during treatment and post-treatment, particularly at the highest concentrations. 
The crude extract displayed a significant (*p<0.05) increase in blood glucose levels on Day 21 
(Fig 4.9 (b)). The plasma insulin concentrations in both non-diabetic and diabetic groups was 
not significantly affected (Fig 4.10). 
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Figure 4.9: Blood glucose responses to M. acetate and crude extract in non-diabetic (a) 
and diabetic (b) Sprague-Dawley rats with respective control groups. Values are presented 
as means ±SEM (n = 6 in each group). *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.10: Effect of M. acetate and crude extract on plasma insulin concentration of 
non-diabetic (a) and diabetic (b) Sprague-Dawley rats with respective control groups. 
Non-treated (NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. 
acetate (MA1.5), 2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are 
presented as means, and vertical bars indicate SEM (n = 6 in each group).  
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4.3.2 Effect of M. acetate and crude extract on water and food intake, urine 
output and body weight changes 
 
Table 4.2 represents the water intake, table 4.3 urine output, table 4.4 food intake and table 4.5 
weight change of the non-diabetic and diabetic groups during pre- treatment, treatment and 
post-treatment. On Day 9, a significant urine output was presented in the non- diabetic control 
(p<0.05) and M. acetate 0.5mg/kg (p<0.01) groups. 
 
On Day 9, a significant (p<0.001 and 0.01) reduction in food intake in the non-diabetic 2.5 and 
1.5mg/kg M. acetate group respectively was observed. On Day 21, a significant (p<0.05) 
increase in food intake in the control and 0.5 mg/kg groups was observed. A significant 
decrease in weight change Day 9 (p<0.001) and 21 (p<0.05) were observed in the non-diabetic 
1.5mg/kg M. acetate group.  
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Table 4.2: Effect of M. acetate, crude extract and Acarbose on water intake of non-
diabetic and diabetic animal’s pre-and post-treatment. 
 
 
 
Experimental Groups 
Water intake (ml) 
 
Pre-
Treatment 
 
Treatment 
 
Post-
Treatment 
Day 0 Day 9 Day 12 Day 21 
 
Non-diabetic animals 
Non-treated 
Control (Tween 20) 
M. acetate (0.5 mg/kg)  
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
 
Diabetic animals 
Non-treated 
Acarbose ((10 mg/kg) 
M. acetate (0.5 mg/kg) 
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
Crude Extract (1.5 mg/kg 
 
 
 
18.33 
18.33                    
21.67   
21.67 
23.33                                                         
 
 
67.50 
57.83 
57.67 
72.50 
70.83 
76.67 
 
 
14.16           
12.50           
10.00            
8.33    
7.50
 
 
72.50 
60.50 
81.17 
82.50 
74.17 
94.67 
 
 
11.67 
17.50 
16.67 
21.25 
9.75
 
 
80.00 
55.00 
87.50 
91.67 
93.33 
86.67 
 
 
22.50 
22.50 
22.50 
25.00 
26.67 
 
 
87.50 
58.33 
90.83 
96.67 
95.83 
80.83 
Values are presented as means ±SEM (n = 6 in each group) 
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Table 4.3: Effect of M. acetate, crude extract and Acarbose on urine output of non-
diabetic and diabetic animal’s pre-and post-treatment. 
 
 
 
Experimental Groups 
Urine output (ml) 
 
Pre-
Treatment 
 
Treatment 
 
Post-
Treatment 
Day 0 Day 9 Day 12 Day 21 
 
Non-diabetic animals 
Non-treated 
Control (Tween 20) 
M. acetate (0.5 mg/kg)  
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
 
Diabetic animals 
Non-treated 
Acarbose ((10 mg/kg) 
M. acetate (0.5 mg/kg) 
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
Crude Extract (1.5 mg/kg 
 
 
 
9.50 
9.66 
10.50 
10.00 
9.83 
 
 
59.00 
46.50 
57.33 
57.33 
57.67 
61.67 
 
 
11.67 
7.33* 
6.66** 
8.66 
7.66 
 
 
67.83 
51.67 
79.33 
69.00 
79.33 
84.50 
 
 
6.66 
5.66 
5.66 
7.00 
7.00 
 
 
71.67 
55.83 
89. 67 
83.00 
93.00 
83.67 
 
 
10.50 
7.33 
7.33 
8.00 
6.66 
 
 
84.00 
54.33 
83.00 
93.00 
91.67 
77.00 
 
Values are presented as means ±SEM (n = 6 in each group). *p<0.05, **p<0.01 
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Table 4.4: Effect of M. acetate, crude extract and Acarbose on food intake of non-diabetic 
and diabetic animal’s pre-and post-treatment. 
 
 
 
 
Experimental 
Groups 
 
Food intake (g) 
 
 
 
Feed conversion 
ratio  
(g) 
 
Pre-
Treatmen
t 
 
Treatment 
 
Post-
Treatme
nt 
 
Day 0 
 
Day 9 
 
Day 12 
 
Day 21 
 
Day 0 
 
Day 21 
Non-diabetic 
animals 
Non-treated 
Control (Tween 20) 
M. acetate (0.5 mg/kg)  
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
 
Diabetic animals 
Non-treated 
Acarbose ((10 mg/kg) 
M. acetate (0.5 mg/kg) 
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
Crude Extract (1.5 
mg/kg 
 
 
 
20.18 
18.94 
21.53 
21.12 
20.05 
 
 
22.40 
18.82 
19.56 
20.46 
20.27 
18.19 
 
 
14.54 
13.67 
11.10 
6.90*** 
7.89** 
 
 
20.96 
21.75 
21.43 
19.10 
22.25 
22.75 
 
 
11.05 
11.21 
11.26 
11.10 
11.75 
 
 
21.25 
21.29 
21.27 
22.02 
22.54 
21.63 
 
 
10.33 
16.64* 
15.92 
13.77 
13.67 
 
 
22.96 
20.55 
18.74 
24.52 
25.57 
18.98 
 
 
1.61 
1.86 
2.01 
2.48 
2.61 
 
 
2.75 
3.06 
3.26 
1.71 
2.43 
    -6.83 
 
 
 
      
     0.19 
0.28 
0.34 
0.40 
0.31 
 
 
1.03 
0.38 
0.57 
0.63 
0.64 
0.54 
Notes: Values are presented as means ±SEM (n = 6 in each group). *p<0.05, **p<0.01, 
***p<0.001. 
Feed conversion ratio was obtained by food intake/weight gain 
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Table 4.5: Effect of M. acetate, crude extract and Acarbose on body weight change of 
non-diabetic and diabetic animal’s pre-and post-treatment. 
 
 
 
 
Experimental 
Groups 
 
Body weight (g) 
 
 
 
Feed conversion 
ratio  
(g) 
 
Pre-
Treatmen
t 
 
Treatment 
 
Post-
Treatme
nt 
 
Day 0 
 
Day 9 
 
Day 12 
 
Day 21 
 
Day 0 
 
Day 21 
Non-diabetic 
animals 
Non-treated 
Control (Tween 20) 
M. acetate (0.5 mg/kg)  
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
 
Diabetic animals 
Non-treated 
Acarbose ((10 mg/kg) 
M. acetate (0.5 mg/kg) 
M. acetate (1.5 mg/kg 
M. acetate (2.5 mg/kg) 
Crude Extract (1.5 
mg/kg 
 
 
 
12.50 
10.17 
10.67 
8.50 
7.66 
 
 
8.16 
6.16 
6.00 
11.83 
8.33 
-2.66 
 
 
22.00 
20.83 
14.83 
5.66 
13.50 
 
 
-5.83 
24.00 
-2.00 
10.50 
7.00 
6.50 
 
 
27.50 
24.33 
21.50 
-9.00*** 
19.75 
 
 
7.66 
29.83 
5.50 
18.33 
12.83 
8.66 
 
 
53.33 
58.83 
45.50 
34.25* 
43.33 
 
 
22.17 
53.83 
32.50 
38.50 
39.67 
34.67 
 
 
1.61 
1.86 
2.01 
2.48 
2.61 
 
 
2.75 
3.06 
3.26 
1.71 
2.43 
-6.83 
 
 
0.19 
0.28 
0.34 
0.40 
0.31 
 
 
1.03 
0.38 
0.57 
0.63 
0.64 
0.54 
Notes: Values are presented as means ±SEM (n = 6 in each group). *p<0.05, ***p<0.001 
Feed conversion ratio was obtained by food intake/weight gain 
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4.3.3 Effect of M. acetate and crude extract on Haematology profile 
                      
Figures 4.11-19 represent the haematological profiles of the non-diabetic and diabetic groups 
on Day 21. The white blood cell and basophil count of the non-diabetic NT group were 
significantly (p<0.05) increased, conversely monocyte and eosinophil count were decreased 
(Fig 4.11, 4.17-19). The diabetic positive control significantly (p<0.05) reduced haematocrit 
(Fig 4.14 (b)). The non-diabetic NT group, significantly reduced white blood cell and red blood 
cell (Fig 4.11 and 4.12). A significant (p<0.05) increase in eosinophil was presented in diabetic 
groups; Acarbose, 1.5mg/kg M. acetate and 2,5mg/kg M. acetate (Fig 4.18 (b)) 
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Figure 4.11: Effect of M. acetate and crude extract on White blood cell count of non-
diabetic (a) and diabetic (b) Sprague-Dawley rats with respective control groups. Non-
treated (NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate 
(MA1.5), 2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented 
as means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
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Figure 4.12: Effect of M. acetate and crude extract on Red blood cell count of non-diabetic 
(a) and diabetic (b) Sprague-Dawley rats with respective control groups.  Non-treated 
(NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
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Figure 4.13: Effect of M. acetate and crude extract on Haemoglobin count of non-diabetic 
(a) and diabetic (b) Sprague-Dawley rats with respective control groups.   Non-treated 
(NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
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Figure 4.14: Effect of M. acetate and crude extract on Haematocrit count of non-diabetic 
(a) and diabetic (b) Sprague-Dawley rats with respective control groups. Non-treated 
(NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
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Figure 4.15: Effect of M. acetate and crude extract on Neutrophil count of non-diabetic 
(a) and diabetic (b) Sprague-Dawley rats with respective control groups. Non-treated 
(NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). **p<0.01. 
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Figure 4.16: Effect of M. acetate and crude extract on Lymphocyte count of non-diabetic 
(a) and diabetic (b) Sprague-Dawley rats with respective control groups. Non-treated 
(NT), Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). 
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Figure 4.17: Effect of M. acetate and crude extract on Monocyte count of non-diabetic (a) 
and diabetic (b) Sprague-Dawley rats with respective control groups. Non-treated (NT), 
Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
          
         
62 
 
                       (a) 
                                
N
T C
0.
5
M
A 1
.5
M
A 2
.5
M
A
0
5
10
15
*
Non-Diabetic Groups
E
O
 (
%
)
 
                       (b) 
N
T A
0.
5
M
A 1
.5
M
A 2
.5
M
A 1
.5
C
E
0
1
2
3
*
*
*
*
*
Diabetic Groups
E
O
 (
%
)
 
Figure 4.18: Effect of M. acetate and crude extract on Eosinophil count of non-diabetic 
(a) and crude (b) Sprague-Dawley rats with respective control groups. Non-treated (NT), 
Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). *p<0.05. 
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Figure 4.19: Effect of M. acetate and crude extract on Basophil count of non-diabetic (a) 
and diabetic (b) Sprague-Dawley rats with respective control groups. Non-treated (NT), 
Control (C), Acarbose (A), 0.5mg/kg M. acetate (MA0.5), 1.5mg/kg M. acetate (MA1.5), 
2.5mg/kg M. acetate (MA2.5) and 1.5mg/kg crude extract (CE1.5). Values are presented as 
means, and vertical bars indicate SEM (n = 6 in each group). **p<0.01. 
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Chapter 5 
Discussion 
 
5.1 In vitro studies 
5.1.1 Glucose utilisation screening and Cytotoxicity Evaluation 
 
Plants have always been a good source of molecules with therapeutic potential, and currently 
represent an important pool in ethnopharmacology for the discovery of novel drugs [130]. The 
use of medicinal plants are presently directed on lowering and controlling blood glucose levels 
in treating diabetes [131]. Thus, medicinal plants have been proven to enhance glucose uptake 
by GLUT4 translocation using in vitro glucose model [132]. In the present study, L6 cell line 
originally derived from rat skeletal muscle was used.  This immortalized myoblast cell line is 
popular as a model for glucose uptake since the cells differentiate with high reliability into a 
myotube muscle cell phenotype that expresses the GLUT4 glucose transporter protein naturally 
[133].   
 
The glucose utilisation of M. acetate at differing doses was found to be prominent over the 
control in a concentration dependant manner. The L6 cell enhanced the glucose utilisation by 
129.41% (3.125 µg/ml), 155.22% (6.25 µg/ml) and 215.18% (12.5 µg/ml). Results were 
compared to insulin, an anabolic hormone which presented a percentage of 171.15 %. A study 
by Kawabata et al. [134]  previously established that triterpernoids isolated from Z. jujuba have 
the ability to effectively enhance glucose utilisation through the translocation of GLUT4. A 
defect in GLUT4 expression and translocation has been stated to be the main metabolic 
irregularity in diabetic skeletal muscle [135]. Furthermore, at higher doses M. acetate 
attenuated glucose utilisation. Reduction of cell viability was seen at higher concentrations 
which may contribute to this observation. M. acetate was observed to be non-toxic at 3 μg/ml 
in L6 cell. In cytotoxicity evaluation, the highest concentration for a test agent should be less 
than 1000 μg/ml to be considered non-toxic [136]. These findings suggest that M. acetate 
demonstrated a considerable hypoglycaemic effect by enhancing the rate of glucose utilisation 
in the L6 cell. The translocation of GLUT 4 may have resulted in the mediation of this 
deduction and may be helpful to manage hyperglycaemia associated with type 2 DM. 
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5.1.2 α- Amylase and α – glucosidase inhibition assay 
 
A major goal in the treatment of DM is to maintain near normal blood glucose levels. One of 
the therapeutic approaches is to decrease postprandial hyperglycaemia by suppressing the 
gastrointestinal tract production or absorption of glucose by inhibition of either α-amylase or 
α-glucosidase enzymes [75]. These are the main enzymes involved in the production of 
glycation end products which may lead to elevated postprandial hyperglycaemia when in 
excess [137]. The capability of plants to supress the production and absorption of glucose has 
demonstrated to be an attractive therapeutic approach in managing DM [49]. In the present 
study, M. acetate and crude extract exhibited an inhibitory effect in a concentration dependent 
manner on both enzymes. The inhibitory effect of M. acetate was more effective than the crude 
extract. At the highest concentration 50 µg/ml, M. acetate showed an inhibitory effect on α- 
amylase and α-glucosidase by 41.01 and 29.61% respectively. It has been shown in literature 
that plants have the ability to inhibit the enzymes, α- amylase and α-glucosidase, in vitro [49, 
75, 125, 138].  Based on these findings, W. salutaris can be considered to possess 
hypoglycaemic effect.  
 
5.1.3 Antioxidant Activity 
 
The malicious effects of diabetes have been established to be mediated through oxidative stress 
which arises from the formation of free radicals. Antioxidant compounds from plants can 
reduce the generation of free radicals, thus, alleviating diseases triggered by oxidative stress 
[139]. The antioxidant activity of M. acetate and crude extract was carried out using DPPH free 
radical scavenging assay, it is apparent that W. salutaris has the ability to scavenge free 
radicals. Similarly, a study by Ai-Dabbas and collaborators [140], showed that the ethanolic 
extracts and compounds isolated from V. iphionoides presented DPPH radical-scavenging 
activity. Furthermore, a study by Frum et al. [122], reported that the methanol and aqueous 
extracts of W. salutaris exhibited promising antioxidant activities. Therefore, these 
observations confirm that W. salutaris possesses antioxidant activity and may provide 
protection against oxidative damage in diabetic patients by neutralizing free radicals. 
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5.2 In vivo studies 
5.2.1 Effect of M. acetate and crude extract on blood glucose and insulin 
levels, body weight change and metabolic parameters 
 
Streptozotocin is a beta cytotoxin used to induce DM by selectively cytotoxicity damaging 
pancreatic beta cells. Thus, affecting endogenous insulin release, resulting in increased blood 
glucose level [141]. In the present study, STZ was employed to induce diabetes in the 
experimental animals. The plasma insulin concentrations were lower in the STZ-induced 
diabetic animals compared to the non-diabetic animals, apparently because of the destructed 
pancreatic β-cells by STZ [142]. Previous studies have shown the antidiabetic activity of plants 
by potentiating insulin resulting in decreased blood glucose levels [143, 144]. The treatment of 
M. acetate and crude extract in the STZ-diabetic animals were incapable of reducing the blood 
glucose levels, with no apparent increase in insulin levels compared to the standard drug 
acarbose. However, the lowest concentration of M. acetate (0.5 mg/kg) presented lower blood 
glucose levels compared to the higher concentrations. In the experiments in vitro, at higher 
concentrations M. acetate attenuated cellular glucose utilisation, giving a probable explanation 
for the observed results.  
 
By comparison with non-diabetic animals, STZ-diabetic animals had reduced body weight gain 
with higher water intake throughout the experimental period. Polydipsia and increased water 
intake resulting from enhanced proteolysis associated with hyperosmotic dehydration has been 
revealed to be related with weight losses in STZ-induced diabetic animals [145]. Treatment 
with M. acetate and crude extract in diabetic animals displayed greater body weights compared 
to diabetic control but not significantly. Thus, indicating that W. salutaris may have a protective 
effect by stabilizing body weight of STZ-induced animals.   
 
5.2.2 Effect of M. acetate and crude extract on haematology parameters 
 
Evaluation of various haematological parameters could be used to determine the deleterious 
effect of foreign compounds including phyto-extracts on the blood constituents of experimental 
animals [146, 147]. The incidence of anaemia in diabetic condition, is due to an increase in the 
non-enzymatic glycosylation of RBC membrane proteins that related with an increase of 
glucose level [147, 148]. In this study, a reduction in the RBC count in the diabetic animals 
was observed which might be attributed to the infections on the normal body systems. This 
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result agrees with report of Sellamuthu et al. [142] who reported the effect of mangiferin 
isolated from S. chinensis on STZ-induced diabetes. It has been established that the deformity 
of RBC causes anaemic disorder in humans [149]. Following treatment with M. acetate and 
crude extract, the RBC count of the diabetic animals was not altered. This indicates that M. 
acetate and crude extract could not stimulate the secretion or formation of erythropoietin, which 
promotes the production of RBC by stimulating stem cells in the bone marrow [146].  
 
The induction of STZ is also known to suppress the immune system by destructing WBC and 
certain organs in the body [146]. A reduction of the WBC count in the diabetic control animals 
was observed in the present study. The reduction could be associated with the destruction of 
leucocytosis from the bone marrow which could account for poor defensive mechanisms 
against infection [150]. Following treatment with M. acetate, WBC count was elevated at 1.5 
and 2.5 mg/kg. Furthermore, M. acetate reduced HCT percentage in STZ-diabetic animals, 
elevation of HCT has been associated with several risk factors of diabetes [151]. However, the 
mechanisms responsible for the affected haematological parameters were not evaluated. The 
measurement of plasma cytokines might possibly provide mechanisms by which these 
parameters were affected.  
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Chapter 6 
Conclusion 
 
The present study aimed to scientifically validate the use of the plant, W. salutaris. The pure 
compound, M. acetate was isolated from the plant and evaluated for the first time for bioactivity 
against diabetes mellitus. The study revealed considerable cytotoxicity of the compound with 
a significant effect on glucose utilisation in vitro. Thus, the translocation of GLUT 4 may have 
resulted in the mediation of the significant glucose utilisation. It was further observed that the 
compound prevented the delivery and absorption of carbohydrates in vitro, by inhibiting the 
key carbohydrate metabolising enzymes. M. acetate also displayed a promising scavenging 
effect on free radicals in vitro. Therefore, in vitro, M. acetate demonstrated a good therapeutic 
efficacy as an antidiabetic and antioxidant.  
 
In vivo, hypoglycaemic activity was not observed in STZ-diabetic animals treated with M. 
acetate and crude extract. Although, M. acetate showed appreciable glucose utilisation in vitro. 
Furthermore, M. acetate was capable of improving some haematological parameters affected 
by induction of STZ. These findings conclude that M. acetate was displayed as a promising 
hypoglycaemic agent in vitro, with no apparent hypoglycaemic effect in vivo. Therefore, 
further studies are required to confirm the therapeutic efficacy of M. acetate. 
 
6.1 Recommendation for future studies 
 
 Antidiabetic activity investigation of M. acetate at lower dosages, in vivo. 
 Elucidate the mechanism of action of M. acetate. 
 Structural modification studies of M. acetate.  
 Evaluation of M. acetate for other pharmacological activities. 
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Appendix A 
Preparation of reagents 
 
A.1 20% sulphuric acid 
 
20 ml of sulphuric was added in 80ml methanol 
 
A.2 Phosphate buffer (pH 7.0) 
 
The buffer contained 13.6g potassium dihydrogen orthophosphate, 17.4g di-potassium 
hydrogen orthophosphate anhydrous, 5.8g sodium chloride, 2g bovine serum albumin and 0.2g 
sodium azide, in 1L dH2O.  
 
A.3 Sodium phosphate buffer (pH 6.9) 
 
The buffer contained 0.29g potassium dihydrogen orthophosphate, 0.34g di-potassium 
hydrogen orthophosphate anhydrous and 0.11g sodium chloride, in 1L dH2O. 
 
A.4 Citrate buffer (pH 4.5) 
 
The buffer contained sodium citrate and citric acid, in 0.5L dH2O. 
 
A.5 Sodium carbonate solution 
 
The solution contained 0.2g sodium carbonate in 10ml dH2O. 
 
A.6 10% Formalin  
 
The buffer contained 100ml formaldehyde, 4g sodium dihydrogen phosphate, 6.5g sodium 
hydrogen phosphate and 900ml dH2O. 
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Appendix B 
Details of methodology 
 
B.1 Chromatographic analysis 
 
Chromatography is a method based on the separation of mixtures into individual components. 
Column chromatography is a technique that consists of a column in which the stationery phase 
of particulate material such as silica or alumina, and the mobile phase is a liquid. The column 
was prepared as follows: cotton was added at the base, with the addition of hexane to avoid air 
bubbles; a thin layer of sea sand; 300g of silica gel mixed with hexane followed; another layer 
of sea sand was added to protect the shape of the extract and lastly 10g of each  crude extract. 
The eluent was slowly passed through the column to advance the crude extract.  
 
Thin layer chromatography is a technique involving a particulate sorbent spread on a sheet of 
glass, plastic, or aluminium foil. The sample is spotted on the sorbent and the mobile phase is 
allowed to move upwards the plate, carrying the sample. The TLC spots were fixed with a 
solution made of 20% H2SO4 in methanol, heated with a hair dryer for colour development 
and visualized under Spectroline UV light at 254nm. The fractions were collected per 80ml 
and accordingly combined through their TLC profiles. 
 
B.2 Structural Elucidation 
B.2.1 NMR  
 
NMR spectroscopy is the study of interaction of radio frequency (RF) of the electromagnetic 
radiation with unpaired nuclear spins in an external magnetic field to obtain structural data on 
a given sample. 
 
B.2.1.1 One Dimensional NMR 
 
Proton nuclear magnetic resonance (1H NMR) is an application which identifies hydrogen 
atoms within the molecules of a substance, in order to determine the structure of its molecules. 
Carbon-13 nuclear magnetic resonance (13C NMR) is an application that identifies carbons in 
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an organic molecule. The NMR measurements were conducted operating at 500 MHz for 1H 
(Fig C1) and 125 MHz for 13C (Fig C2) using CDCL3. 
 
B2.1.2 Two dimensional NMR 
 
Distortionless enhancement of polarisation transfer (DEPT) is an application where the nuclei 
of interest are carbon -13 nuclei, the signals from which are enhanced by the transfer of 
magnetisation from 1H nuclei. DEPT was operated at 125 MHz using CDCL3. Correlation 
spectroscopy (COSY) is a 2D NMR application for determining which signals arise from 
neighbouring protons. NMR measurement were conducted at 400 MHz using CDCL3, both 
axes show 1H-NMR of the compound (Fig C4) 
Nuclear overhauser effect spectroscopy (NOESY) is an application used to determine the intra- 
or inter-molecular distances. NOESY was operated at 500 MHz using CDCL3, it shows which 
protons are nearer to each other in space by drawing a straight line from any of the dark spots 
to each axis of the plot (Fig C5). Heteronuclear single-quantum correlation spectroscopy 
(HSQC) is an application that shows correlation between directly bonded 1H and an X-
heteronuclei, usually 13C and 15N. HSQC was operated at 500 MHz using CDCL3 (Fig C6). 
Heteronuclear multiple bond correlation (HMBC) is an application that gives correlations 
between carbons and protons that are separated by two, three and sometimes conjugated 
systems, four bonds. HMBC was operated at 500 MHz using CDCL3, the abscissa of the 
spectrum shows the proton signals, and the ordinate shows the carbon signals. The spots in the 
spectrum indicate which protons signal is attached to which carbon and the nature of the signals 
(Fig C7). 
 
B3 Mass Spectroscopy (MS) 
 
MS is an application that generates charged particles (ions) from the molecules of the analyte. 
The ions are thereafter analysed to provide information on the molecular weight of the 
compound and its structure. 
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B4 Infrared spectroscopy 
 
Infrared Spectroscopy is the analysis of infrared light interacting with a molecule. It measures 
the vibrations of atoms, and based on this it is possible to determine the functional groups. 
 
B5 X-ray crystallography 
 
X-ray crystallography is an instrument used to determine the atomic and molecular structure 
of a crystal. The crystalline atoms cause a beam of incident X-rays, diffracting into numerous 
precise directions. The compound Mukaadial Acetate was recrystallized using the solvent 
hexane as follows; it was simmered in the solvent for 5-10 min and thereafter, left to evaporate 
at room temperature to obtain cryst. 
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Appendix C 
Spectra 
 
SpinWorks 4: NN-01 in CDCl3 
 
 file: ..._nn01_cdcl3_1h.20160419.nmr5\1\fid   expt: <zg30> freq. of 0 ppm: 500.010012 MHz  transmitter freq.: 500.013750 MHz processed size: 65536 complex points 
time domain size: 131072 points LB: 0.300    GF: 0.0000 width: 13513.51 Hz = 27.0263 ppm = 0.103100 Hz/pt 
number of scans: 32 
 
Figure C1: 1H Spectrum of Mukaadial acetate in CDCL3. 
 
SpinWorks 4: NN-01 in CDCl3 
 
PPM 180 160 140 120  100 80 60 40 20 
file: ...nn01_cdcl3_13c.20160419.nmr5\1\fid   expt: 
<zgpg30> transmitter freq.: 125.741445 MHz time domain 
size: 65536 points 
width: 32894.74 Hz = 261.6062 ppm = 0.501934 Hz/pt 
number of scans: 512 
 
freq. of 0 ppm: 125.727615 MHz 
processed size: 32768 complex points 
LB: 1.000    GF: 0.0000 
   
Figure C2: 13C Spectrum of Mukaadial acetate in CDCL3. 
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SpinWorks 4: NN-01 in CDCl3 
 
PPM 160 120 80 40 0 
file: ..._cdcl3_dept135.20160419.nmr5\1\fid   expt: 
<dept135> transmitter freq.: 125.740187 MHz time domain 
size: 65536 points 
width: 29761.90 Hz = 236.6937 ppm = 0.454131 Hz/pt 
number of scans: 128 
 
freq. of 0 ppm: 125.727615 MHz 
processed size: 32768 complex points 
LB: 1.000    GF: 0.0000 
  
 
Figure C3: DEPT Spectrum of Mukaadial acetate in CDCL3. 
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expt: <cosygpmfqf> processed size: 1024 complex points processed size: 1024 complex points transmitter freq: 400.222106 MHz window function: 
Sine window function: Sine time domain size: 2048 by 97 points shift: 0.0 degrees shift: 0.0 degrees width (F2): 4132.23 Hz = 10.3248 ppm = 
2.0177 Hz/pt number of scans:  
Figure C4: COSY Spectrum of Mukaadial acetate in CDCL3. 
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expt: <noesygpph> processed size: 1024 complex pointsprocessed size: 1024 complex points transmitter freq: 500.012689 MHz window function: Sine Squared
 window function: Sine Squared time domain size: 2048 by 256 points shift: 90.0 degrees shift: 90.0 degrees width (F2): 
5466.47 Hz = 10.9327 ppm = 2.6692 Hz/pt number of scans: 8 
 
Figure C5: NOESY Spectrum of Mukaardial acetate in CDCL3. 
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expt: <hsqcetgp> processed size: 1024 complex points processed size: 1024 complex points transmitter freq: 500.012706 MHz window function: 
Sine Squared window function: Sine Squared time domain size: 1024 by 256 points shift: 90.0 degrees shift: 90.0 degrees width (F2): 
5747.13 Hz = 11.4940 ppm = 5.6124 Hz/pt number of scans: 2 
  
 
Figure C6: HSQC Spectrum of Mukaadial acetate in CDCL3. 
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expt: <hmbcgplpndqf> processed size: 2048 complex points processed size: 1024 complex points transmitter freq: 500.012706 MHz window function: 
Sine window function: Sine time domain size: 4096 by 128 points shift: 0.0 degrees shift: 0.0 degrees width (F2): 5747.13 Hz = 11.4940 ppm = 
1.4031 Hz/pt number of scans: 8 
 
Figure C7: HMBC Spectrum of Mukaadial acetate in CDCL3. 
 
 
 
 
 
 
86 
 
 
Figure C8: IR spectra for Mukadial acetate  
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Contribution to Knowledge 
 
